Abstract
Long-Term Safety, Efficacy, and Survival Findings From Comfort-II, a Phase 3 Study Comparing Ruxolitinib with Best Available Therapy (BAT) for the Treatment of Myelofibrosis (MF)
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have